FILING ANALYSIS · TUESDAY, OCTOBER 27
Aclaris Therapeutics, Inc. ACRS — 8-K: Entry into a Material Definitive Agreement
negative
The company is raising approximately $46.7 million in net proceeds through an underwritten offering of 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares of common stock, which will result in dilution to existing shareholders. The offering price is $3.50 per share of common stock and $3.49999 per pre-funded warrant.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →